Table 2.
Sample to residual ratio quantification using RRT-PCR results for known IBV strains
| Strain | Serotypea | Anti-Massachusetts | Anti-Arkansas | Anti-Connecticut | Anti-Delaware/Georgia 98 | Assay serotype |
|---|---|---|---|---|---|---|
| Beaudette | Massachusetts | +b (4.74) | −c (−1.15) | − (−0.80) | − (0.03) | Massachusetts |
| Florida 18288 | Florida | − (−0.80) | − (−1.70) | − (−1.47) | − (−1.85) | Not typeable |
| Arkansas 99 | Arkansas | − (−1.13) | + (3.35) | − (−1.70) | − (−2.46) | Arkansas |
| 3668-4 | Arkansas | − (−0.82) | + (2.48) | − (−0.66) | − (−0.37) | Arkansas |
| GAV92/4595/92 | GAV92 | − (0.16) | − (0.85) | − (0.65) | − (−1.01) | Not typeable |
| 0470 | GA98 | − (−0.29) | − (−0.55) | − (−1.27) | + (2.06) | Delaware/GA98 |
| CAV 56b | California Variant | − (−0.22) | − (0.27) | − (−0.48) | − (0.5) | Not typeable |
| 15172 C | Nebraska 95 | − (−0.51) | − (0.55) | − (−0.99) | − (−1.17) | Not typeable |
Calculated SRRQ values are given in parentheses.
a
Serotype as determined by virus neutralization or RT-PCR/RFLP.
b
A plus sign denotes that the sample RNA incubated with the particular chimeric oligonucleotide amplified at least two cycles later as compared with the uncleaved control RNA.
c
A negative sign denotes that the sample RNA incubated with the particular chimeric oligonucleotide amplified no later than 1.99 cycles as compared with the uncleaved control RNA.